Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesBevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast CancerUse of bevacizumab as a first-line treatment for metastatic breast cancer.Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-AnalysisClinical implications of molecular heterogeneity in triple negative breast cancer.IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsBevacizumab: a review of its use in advanced cancer.Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.Autophagy, a double-edged sword in anti-angiogenesis therapy.Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?Triple negative breast cancer: the kiss of death.The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database.Role of tumor microenvironment in triple-negative breast cancer and its prognostic significancePrognosis of invasive breast cancer after adjuvant therapy evaluated with VEGF microvessel density and microvascular imaging.Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.Comparative study of polymorphism frequencies of the CYP2D6, CYP3A5, CYP2C8 and IL-10 genes in Mexican and Spanish women with breast cancer.VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities.Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.
P2860
Q26822432-E4254425-E665-4B13-BB73-0179FDD70377Q28080469-E3F0B2D7-A147-4597-A751-E7B2298C20A6Q33424566-7BF141E4-F831-409D-9037-8EF4EA7EF640Q34080323-206D2260-04E0-4827-8FE4-DD6E07CC22F2Q35445151-043BEF64-8F88-46E6-944F-C212D2CC3DD3Q36118278-284F0693-05F1-43D0-BC1B-54481F54771DQ36271396-22E7A4DF-D2AC-482A-9724-00365E58C68DQ37725536-F1B70F3A-1A99-4E62-9588-66C439AE5EF0Q38260176-B0C0C249-32DA-4AB9-AE99-9CC5AA51A741Q38308001-96DC6958-3C0E-46F0-A38E-4A8E366092CAQ38682453-33214CA1-BE97-4414-B991-8F30C6CBA815Q38711157-890FCAD0-EB9B-495F-9A1D-CA01C57445E8Q38818744-9371833A-6C76-4B70-9E74-C4CF5947B9B3Q38878437-D9CC47DB-EFD3-4654-8DC9-2380A630764EQ39179354-7AEFC7F0-129A-4296-A65A-311731FB254EQ39449113-784A9EAE-A2DB-4A7A-8F04-02AD382A9D16Q40860774-BDE0771C-1A43-444D-B08A-596C468AC9C2Q41742917-10CFB3BB-D257-4AD6-B9D2-167302B092EBQ43477148-E9A2F508-FB8F-4117-8C3C-6A0FE5D51E6FQ46126845-511F83FD-89F2-499E-A936-BA2CCDB19BE2Q46721561-314A22D8-FBBA-4DCF-B29D-ABD1EA137570Q48848074-6C2F45B1-4343-4803-BE41-CB10463AF677Q49874623-8CD8457D-4851-4A2F-AD11-599416D17EBDQ53752984-8145E5E7-279C-413A-933D-DA7436A08410Q53834125-9BC7AF9A-F5CF-4E52-A233-161339221A2F
P2860
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@ast
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@en
type
label
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@ast
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@en
prefLabel
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@ast
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@en
P2093
P2860
P1476
Prognostic and predictive valu ...... ; results from ECOG 2100 trial
@en
P2093
Bryan P Schneider
Edith A Perez
George W Sledge
Guanglong Jiang
Joseph A Sparano
Julie R Gralow
Kathy D Miller
Kirsten Vang Nielsen
P2860
P304
P356
10.1158/1078-0432.CCR-12-3029
P407
P577
2013-01-22T00:00:00Z